EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSONIG00000011507
Gene Symbol: LOC100693467
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSONIG00000041577
Gene Symbol: KCNH2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSONIG00000019476
Gene Symbol: KCNQ2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSONIG00000012378
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSONIG00000001209
Gene Symbol: KCNQ5
3 Cross references
196 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSONIG00000009352
Gene Symbol: KCNQ2A
1 Cross references
185 Possible Orthologues:

Presenilin-2

Ensembl ID : ENSONIG00000006843
Gene Symbol: LOC100710620
4 Cross references
205 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme

Ensembl ID : ENSONIG00000011903
Gene Symbol: LOC100705916
3 Cross references
404 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSONIG00000007720
Gene Symbol: LOC100691799
4 Cross references
250 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSONIG00000041442
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSONIG00000021243
Gene Symbol: PTGDR2
4 Cross references
135 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSONIG00000003470
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).